{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:45:01Z","timestamp":1761101101619},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9,15]]},"DOI":"10.2146\/ajhp110540","type":"journal-article","created":{"date-parts":[[2012,8,30]],"date-time":"2012-08-30T12:16:26Z","timestamp":1346328986000},"page":"1559-1567","source":"Crossref","is-referenced-by-count":11,"title":["Direct thrombin inhibitors for management of heparin-induced thrombocytopenia in patients receiving renal replacement therapy: Comparison of clinical outcomes"],"prefix":"10.1093","volume":"69","author":[{"given":"Erik E.","family":"Abel","sequence":"first","affiliation":[{"name":"The Ohio State University Medical Center, Columbus; at the time this study was conducted, he was Postgraduate Year 2 Resident in Cardiology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra L.","family":"Kane-Gill","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, and Critical Care Medication Safety Officer, Department of Pharmacy, UPMC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy L.","family":"Seybert","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, and Cardiovascular Clinical Pharmacist, UPMC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Kellum","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041204012710300_b1-0691559","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1001\/archinte.164.18.1961","article-title":"Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient)","volume":"164","author":"Rice","year":"2004","journal-title":"Arch Intern Med."},{"key":"2019041204012710300_b2-0691559","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev.med.50.1.129","article-title":"Heparin-induced thrombocytopenia: a ten-year retrospective","volume":"50","author":"Warkentin","year":"1999","journal-title":"Annu Rev Med."},{"key":"2019041204012710300_b3-0691559","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9343(96)00258-6","article-title":"A 14-year study of heparin-induced thrombocytopenia","volume":"101","author":"Warkentin","year":"1996","journal-title":"Am J Med."},{"key":"2019041204012710300_b4-0691559","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1592\/phco.28.9.1115","article-title":"Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia","volume":"28","author":"Kiser","year":"2008","journal-title":"Pharmacotherapy."},{"key":"2019041204012710300_b5-0691559","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1592\/phco.26.4.452","article-title":"Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and\/or renal dysfunction","volume":"26","author":"Kiser","year":"2006","journal-title":"Pharmacotherapy."},{"key":"2019041204012710300_b6-0691559","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1592\/phco.30.11.1117","article-title":"Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy","volume":"30","author":"Kiser","year":"2010","journal-title":"Pharmacotherapy."},{"key":"2019041204012710300_b7-0691559","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ajh.21955","article-title":"Evaluation of empiric versus nomogram-based direct thrombin inhibitor management in patients with suspected heparin-induced thrombocytopenia","volume":"86","author":"Kiser","year":"2011","journal-title":"Am J Hematol."},{"key":"2019041204012710300_b8-0691559","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1538-7836.2006.01787.x","article-title":"Evaluation of pretest clinical score (4 T\u2019s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings","volume":"4","author":"Lo","year":"2006","journal-title":"J Thromb Haemost."},{"key":"2019041204012710300_b9-0691559","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1592\/phco.30.12.1229","article-title":"Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia","volume":"30","author":"Skrupky","year":"2010","journal-title":"Pharmacotherapy."},{"key":"2019041204012710300_b10-0691559","volume-title":"Refludan (lepirudin) package insert","year":"2006"},{"key":"2019041204012710300_b11-0691559","volume-title":"Argatroban package insert","year":"2009"},{"key":"2019041204012710300_b12-0691559","volume-title":"Angiomax (bivalirudin) package insert","year":"2005"},{"key":"2019041204012710300_b13-0691559","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ackd.2010.06.002","article-title":"Systemic anticoagulation considerations in chronic kidney disease","volume":"17","author":"Dager","year":"2010","journal-title":"Adv Chronic Kidney Dis."},{"key":"2019041204012710300_b14-0691559","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1345\/aph.1M179","article-title":"Prefilter bivalirudin for preventing hemofilter occlusion in continuous renal replacement therapy","volume":"43","author":"Mueller","year":"2009","journal-title":"Ann Pharmacother."},{"key":"2019041204012710300_b15-0691559","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/08860220600843813","article-title":"Heparin-induced thrombocytopenia in patients administered heparin solely for hemodialysis","volume":"28","author":"Murray","year":"2006","journal-title":"Ren Fail."},{"key":"2019041204012710300_b16-0691559","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1525-139X.2008.00545.x","article-title":"Anticoagulation for continuous renal replacement therapy","volume":"22","author":"Tolwani","year":"2009","journal-title":"Semin Dial."},{"key":"2019041204012710300_b17-0691559","volume-title":"Heparin-induced thrombocytopenia","author":"Warkentin","year":"2004","edition":"3rd ed"},{"key":"2019041204012710300_b18-0691559","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2011.08746.x","article-title":"Heparin-induced thrombocytopenia: analysis of risk factors in medical inpatients","volume":"154","author":"Kato","year":"2011","journal-title":"Br J Haematol."},{"key":"2019041204012710300_b19-0691559","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0049-3848(97)00301-0","article-title":"Platelet count, anti-heparin\/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis","volume":"89","author":"Luzzatto","year":"1998","journal-title":"Thromb Res."},{"key":"2019041204012710300_b20-0691559","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0272-6386(96)90134-1","article-title":"Heparin-induced thrombocytopenia in hemodialysis patients","volume":"28","author":"Yamamoto","year":"1996","journal-title":"Am J Kidney Dis."},{"issue":"(suppl)","key":"2019041204012710300_b21-0691559","doi-asserted-by":"crossref","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest."},{"key":"2019041204012710300_b22-0691559","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1345\/aph.10282","article-title":"Use of lepirudin in patients with heparin-induced thrombocytopenia and renal failure requiring hemodialysis","volume":"35","author":"Dager","year":"2001","journal-title":"Ann Pharmacother."},{"key":"2019041204012710300_b23-0691559","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1067\/mcp.2002.124522","article-title":"Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender","volume":"71","author":"Robson","year":"2002","journal-title":"Clin Pharmacol Ther."},{"key":"2019041204012710300_b24-0691559","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1345\/aph.1G033","article-title":"Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy","volume":"39","author":"Reddy","year":"2005","journal-title":"Ann Pharmacother."},{"key":"2019041204012710300_b25-0691559","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1345\/aph.1D163","article-title":"Effect of renal function on the pharmacodynamics of argatroban","volume":"38","author":"Arpino","year":"2004","journal-title":"Ann Pharmacother."},{"key":"2019041204012710300_b26-0691559","first-page":"249","article-title":"Comparison of in vitro and in vivo properties of hirudin (HBW 023) and a synthetic analogous peptide","volume":"23","author":"Romisch","year":"1993","journal-title":"Haemostasis."},{"key":"2019041204012710300_b27-0691559","doi-asserted-by":"crossref","first-page":"14807","DOI":"10.1021\/bi00253a020","article-title":"Kinetic mechanism for the interaction of Hirulog with thrombin","volume":"33","author":"Parry","year":"1994","journal-title":"Biochemistry."},{"key":"2019041204012710300_b28-0691559","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol."},{"key":"2019041204012710300_b29-0691559","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jclinepi.2005.11.013","article-title":"A user\u2019s guide to selecting a comorbidity index for clinical research","volume":"59","author":"Hall","year":"2006","journal-title":"J Clin Epidemiol."},{"key":"2019041204012710300_b30-0691559","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0895-4356(93)90103-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives","volume":"46","author":"Romano","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"2019041204012710300_b31-0691559","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol."},{"key":"2019041204012710300_b32-0691559","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1160\/TH04-12-0825","article-title":"Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients","volume":"94","author":"Greinacher","year":"2005","journal-title":"Thromb Haemost."},{"key":"2019041204012710300_b33-0691559","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.76.1.142","article-title":"Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge","volume":"76","author":"Chesebro","year":"1987","journal-title":"Circulation."},{"issue":"(suppl)","key":"2019041204012710300_b34-0691559","doi-asserted-by":"crossref","first-page":"311S","DOI":"10.1378\/chest.126.3_suppl.311S","article-title":"Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Warkentin","year":"2004","journal-title":"Chest."},{"issue":"(suppl)","key":"2019041204012710300_b35-0691559","doi-asserted-by":"crossref","first-page":"340S","DOI":"10.1378\/chest.08-0677","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"Warkentin","year":"2008","journal-title":"Chest."},{"key":"2019041204012710300_b36-0691559","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/ajh.20820","article-title":"Lepirudin for anticoagulation in patients with heparin-induced thrombocytopenia treated with continuous renal replacement therapy","volume":"82","author":"Gajra","year":"2007","journal-title":"Am J Hematol."},{"key":"2019041204012710300_b37-0691559","doi-asserted-by":"crossref","first-page":"c80","DOI":"10.1159\/000139993","article-title":"Argatroban anticoagulation in renal dysfunction: a literature analysis","volume":"109","author":"Hursting","year":"2008","journal-title":"Nephron Clin Pract."},{"key":"2019041204012710300_b38-0691559","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1345\/aph.1L224","article-title":"Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia","volume":"43","author":"Keegan","year":"2009","journal-title":"Ann Pharmacother."},{"key":"2019041204012710300_b39-0691559","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/cc9024","article-title":"Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study","volume":"14","author":"Saugel","year":"2010","journal-title":"Crit Care."},{"key":"2019041204012710300_b40-0691559","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1592\/phco.29.9.1073","article-title":"Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients","volume":"29","author":"Smythe","year":"2009","journal-title":"Pharmacotherapy."},{"key":"2019041204012710300_b41-0691559","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","article-title":"Thrombolysis in Myocardial Infarction (TIMI) trial\u2014phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase","volume":"11","author":"Rao","year":"1988","journal-title":"J Am Coll Cardiol."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/69\/18\/1559\/28361850\/ajhp1559.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T20:03:20Z","timestamp":1555099400000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/69\/18\/1559\/5111897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,15]]},"references-count":41,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2012,9,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp110540","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,9,15]]},"published":{"date-parts":[[2012,9,15]]}}}